Details of the Drug Combination

General Information of Drug Combination (ID: DCQOYSF)

• Drug Combination Name: Estramustine + SCH-900776
• Indication: Ovarian endometrioid adenocarcinoma; Status: Investigative [1]
• Component Drugs:
  Estramustine (DMWTAOI): Small molecular drug
  SCH-900776 (DM67EMK): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: A2780
  Zero Interaction Potency (ZIP) Score: 12.75
  Bliss Independence Score: 14.86
  Loewe Additivity Score: 16.87
  LHighest Single Agent (HSA) Score: 19.04

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Estramustine

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[2]

Estramustine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Estramustine binding protein (EMBP)	TTSBFYK	NOUNIPROTAC	Binder	[4]

Estramustine Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[5]

Estramustine Interacts with 2 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Keratin, type I cytoskeletal 18 (KRT18)	OTVLQFIP	K1C18_HUMAN	Increases Expression	[6]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Increases Phosphorylation	[7]

Indication(s) of SCH-900776

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]

SCH-900776 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Checkpoint kinase-1 (CHK1)	TTTU902	CHK1_HUMAN	Inhibitor	[8]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour	DCKJ8Q5	ES2	Investigative	[9]
Breast and ovarian cancer syndrome	DCZQZ8O	UWB1289	Investigative	[10]
Breast and ovarian cancer syndrome	DC6PA6A	UWB1289+BRCA1	Investigative	[10]
Breast carcinoma	DCMVT6M	KPL1	Investigative	[10]
Breast carcinoma	DCTOA3M	OCUBM	Investigative	[10]
Carcinoma	DCD8FR0	OV90	Investigative	[10]
Carcinoma	DCVAV01	EFM192B	Investigative	[10]
Carcinoma	DCH7NKT	MDAMB436	Investigative	[10]
Colon adenocarcinoma	DCGL4IA	LOVO	Investigative	[10]
Invasive ductal carcinoma	DCYEI30	T-47D	Investigative	[10]
Adenocarcinoma	DCVOP7Q	CAOV3	Investigative	[1]
Adenocarcinoma	DC12K7A	OVCAR3	Investigative	[1]
Adenocarcinoma	DCGWSD1	NCIH23	Investigative	[1]
Adenocarcinoma	DCODMCR	NCIH520	Investigative	[1]
Adenocarcinoma	DCASNHG	COLO320DM	Investigative	[1]
Adenocarcinoma	DC8NXMH	HT29	Investigative	[1]
Amelanotic melanoma	DC8KCAR	A2058	Investigative	[1]
Germ cell tumour	DCHN4GA	PA1	Investigative	[1]
Large cell lung carcinoma	DCBXIRD	NCI-H460	Investigative	[1]
Malignant melanoma	DC9MSVH	A375	Investigative	[1]
Malignant melanoma	DCVGC4Q	HT144	Investigative	[1]
Malignant melanoma	DCV6X24	RPMI7951	Investigative	[1]
Malignant melanoma	DCBSU7P	SKMEL30	Investigative	[1]
Malignant melanoma	DCHM2QK	UACC62	Investigative	[1]
Mesothelioma	DC5PIBS	MSTO	Investigative	[1]
Non small cell carcinoma	DC47NSK	SKMES1	Investigative	[1]
Ovarian serous cystadenocarcinoma	DC1XDU9	SK-OV-3	Investigative	[1]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7943).
• [4] Estramustine binding protein in primary tumours and metastases of malignant melanoma. Melanoma Res. 1994 Dec;4(6):401-5.
• [5] Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol. 2003 May;169(5):1729-34.
• [6] Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer. 2006 Jun 5;94(11):1592-8. doi: 10.1038/sj.bjc.6603129.
• [7] Induction of apoptosis by estramustine phosphate mediated by phosphorylation of bcl-2. J Neurooncol. 2001 Aug;54(1):23-9. doi: 10.1023/a:1012566601485.
• [8] Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
• [9] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [10] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.